We are live on
!
Find out more
BCM
Bayesian Capital Management Portfolio holdings
AUM
$156M
1-Year Est. Return
14.89%
This Fund
S&P 500
This Quarter
Est. Return
+11.11%
1 Year Est. Return
+14.89%
3 Year Est. Return
+106.87%
5 Year Est. Return
+133.82%
10 Year Est. Return
+1,146.09%
AUM
$585M
AUM Growth
+$56.2M
(+11%)
Cap. Flow
+$17.6M
Cap. Flow
% of AUM
3.01%
Top 10 Holdings %
Top 10 Hldgs %
17.05%
Holding
830
New
329
Increased
104
Reduced
143
Closed
252
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$33.9M |
| 2 |
Verizon
VZ
|
+$6.56M |
| 3 |
Lowe's Companies
LOW
|
+$6.21M |
| 4 |
Procter & Gamble
PG
|
+$6.15M |
| 5 |
Danaher
DHR
|
+$5.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Accenture
ACN
|
+$12.8M |
| 2 |
Meta Platforms (Facebook)
META
|
+$11.3M |
| 3 |
Apple
AAPL
|
+$11.1M |
| 4 |
UnitedHealth
UNH
|
+$9.36M |
| 5 |
McCormick & Company Non-Voting
MKC
|
+$6.64M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.76% |
| 2 | Consumer Discretionary | 14.7% |
| 3 | Healthcare | 14.64% |
| 4 | Consumer Staples | 12.4% |
| 5 | Miscellaneous | 11.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
INFN
451
DELISTED
Infinera Corporation Common Stock
INFN
| $274K | 0.05% |
+34,500
| New | +$212K |
|
|
INOV
452
DELISTED
Inovalon Holdings, Inc. Class A Common Stock
INOV
| $273K | 0.05% |
+14,500
| New | +$243K |
|
453
Monolithic Power Systems
MPWR
$64.4B
| $271K | 0.05% |
+1,524
| New | +$243K |
|
454
BCE
BCE
$21.8B
| $270K | 0.05% |
+5,823
| New | +$279K |
|
455
Entergy
ETR
$49.7B
| $269K | 0.05% |
+4,494
| New | +$265K |
|
456
Vanda Pharmaceuticals
VNDA
$329M
| $269K | 0.05% |
+16,400
| New | +$248K |
|
457
Wabtec
WAB
$50.2B
| $269K | 0.05% |
+3,464
| New | +$256K |
|
|
PTLA
458
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $268K | 0.05% |
+11,222
| New | +$310K |
|
459
NextEra Energy
NEE
$174B
| $266K | 0.05% |
+4,400
| New | +$257K |
|
460
Sanofi
SNY
$107B
| $265K | 0.05% |
5,283
-3,917
| -43% | -$183K |
|
461
Essent Group
ESNT
$6.23B
| $264K | 0.05% |
+5,083
| New | +$265K |
|
|
FITB
462
Fifth Third Bancorp
FITB
$49.7B
| $264K | 0.05% |
+8,600
| New | +$252K |
|
463
Unifirst Corp
UNF
$5.17B
| $264K | 0.05% |
1,305
-3,386
| -72% | -$687K |
|
464
CME Group
CME
$101B
| $261K | 0.04% |
+1,300
| New | +$267K |
|
465
Darling Ingredients
DAR
$9.69B
| $261K | 0.04% |
+9,300
| New | +$207K |
|
466
RH
RH
$2.74B
| $261K | 0.04% |
1,222
-7,439
| -86% | -$1.45M |
|
467
Zoetis
ZTS
$31B
| $261K | 0.04% |
1,973
-5,527
| -74% | -$687K |
|
468
B&G Foods
BGS
$282M
| $258K | 0.04% |
+14,388
| New | +$242K |
|
469
Huron Consulting
HURN
$2.54B
| $258K | 0.04% |
3,761
+400
| +12% | +$26K |
|
|
MRC
470
DELISTED
MRC Global
MRC
| $257K | 0.04% |
+18,860
| New | +$246K |
|
471
Ametek
AME
$55.9B
| $254K | 0.04% |
+2,542
| New | +$241K |
|
472
Scholastic
SCHL
$738M
| $254K | 0.04% |
+6,600
| New | +$249K |
|
473
Graphic Packaging
GPK
$3.35B
| $253K | 0.04% |
15,183
-27,200
| -64% | -$431K |
|
474
UFP Industries
UFPI
$4.71B
| $253K | 0.04% |
5,300
-7,517
| -59% | -$354K |
|
475
Acadia Pharmaceuticals
ACAD
$5.12B
| $252K | 0.04% |
+5,900
| New | +$257K |
|
Similar funds
MCM
MFG
AFW
ADBIC
HSM
FWM
PIA
CCP
Bayesian Capital Management's Q4 2019 Portfolio in Review
As of Q4 2019, Bayesian Capital Management held 830 positions worth $585M, up 11% from $529M the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Bayesian Capital Management deployed $17.6M of net new capital in Q4 2019, opening 329 new positions and adding to 104 existing holdings. Its largest new stake was State Street SPDR S&P 500 ETF Trust: 110,200 shares worth $35.5M.
By sector, the portfolio is most concentrated in Technology at 18% of assets, down from 23% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was Meta Platforms (Facebook), an estimated $11.3M trimmed.
- Bayesian Capital Management's largest Q4 2019 buy was State Street SPDR S&P 500 ETF Trust: 110,200 shares worth $35.5M.
- Bayesian Capital Management added most to Edwards Lifesciences in Q4 2019, an estimated $4.47M increase.
- Bayesian Capital Management's biggest Q4 2019 reduction was Meta Platforms (Facebook), cutting an estimated $11.3M.
- Bayesian Capital Management fully exited Accenture in Q4 2019, selling an estimated $12.8M.
- Bayesian Capital Management's ten largest holdings make up 17% of its $585M portfolio in Q4 2019.
- Bayesian Capital Management opened 329 new positions and closed 252 in Q4 2019.
- Bayesian Capital Management's portfolio value rose 11% quarter-over-quarter to $585M.
Based on Bayesian Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.